This article needs additional citations for verification. (September 2024) |
Clinical data | |
---|---|
Trade names | Duricef |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682730 |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | plasma protein |
Metabolism | unknown |
Elimination half-life | 1.5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.051.397 |
Chemical and physical data | |
Formula | C16H17N3O5S |
Molar mass | 363.39 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cefadroxil (formerly trademarked as Duricef) is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections. It is a bactericidal antibiotic.
It was patented in 1967 and approved for medical use in 1978.[1]